Drugs / HLA-mismatched peripheral blood stem cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05095558 | Oct 2021 → Oct 2023 | ovarian carcinoma | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT04937842 | Jun 2021 → May 2023 | cancer | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLA-mismatched peripheral blood stem cells | “infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)” NCT04937842 ↗1“infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)” NCT05095558 ↗ |
| Known as | GPBSC | “infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)” NCT04937842 ↗1“infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)” NCT05095558 ↗ |
| Modality | Cell therapy | “peripheral blood hematopoietic stem cells from HLA mismatched donors mobilized with granulocyte colony stimulating factor are infused” NCT05095558 ↗ |